In addition to characterizing the genetic basis for different cancers, scientists are increasingly interested in the role of the epigenome in tumor development, and possible therapies that can target genes repressed by chemically modifying chromatin in cancer.
Part of what makes the epigenome an attractive target is the possibility of hitting a system of proteins involved in gene expression programming rather than a single target, according to Karmella Haynes, PhD, an assistant professor of biomedical engineering at Emory University. She and a team of scientists from Emory University and Georgia Institute of Technology have developed another potential approach for reactivating repressed tumor suppressor genes that could ultimately have implications for how solid tumors like triple-negative breast cancer (TNBC) are treated… Continue reading.
...WASHINGTON, D.C. — The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Karmella A. Haynes, Ph.D., Assistant Professor at Emory University to its College of Fellows.
Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering or developing/implementing innovative approaches to bioengineering education… Continue reading.
...